A Correlation Between Differentiation Phenotypes of Infused T Cells and Anti-Cancer Immunotherapy.
A Correlation Between Differentiation Phenotypes of Infused T Cells and Anti-Cancer Immunotherapy.
复制标题
DOI：
10.3389/fimmu.2021.745109
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Wang M
中科院分区：
文献类型：
--
作者：
Ren H;Cao K;Wang M
T细胞疗法，通常具有离体扩增，非常有希望治疗癌症。输注的T细胞的分化状态是其持久性和抗肿瘤免疫的关键参数。关键表型分子是分析分化状态的有效和高效的分子。分化状态对于T细胞耗竭、体内寿命、抗肿瘤免疫甚至抗肿瘤药理学干预至关重要。已经开发了包括细胞因子、Akt、Wnt和Notch信号传导、表观遗传学和代谢物的策略来产生分化程度较低的T细胞。临床试验显示，输注分化程度较低的T细胞的临床结果更好。CD27+、CCR7+和CD62L+是临床上最相关的表型分子，而Tscm和Tcm是临床上最相关的亚型。目前，推荐在分化表型中使用CD27+、CD62L+和CCR7+来评估增强干细胞性的策略。未来的研究可能会发现特定T细胞生产方法或癌症患者特定亚型的高度临床相关的分化表型，具有精准医疗的优势。
T-cell therapy, usually with ex-vivo expansion, is very promising to treat cancer. Differentiation status of infused T cells is a crucial parameter for their persistence and antitumor immunity. Key phenotypic molecules are effective and efficient to analyze differentiation status. Differentiation status is crucial for T cell exhaustion, in-vivo lifespan, antitumor immunity, and even antitumor pharmacological interventions. Strategies including cytokines, Akt, Wnt and Notch signaling, epigenetics, and metabolites have been developed to produce less differentiated T cells. Clinical trials have shown better clinical outcomes from infusion of T cells with less differentiated phenotypes. CD27+, CCR7+ and CD62L+ have been the most clinically relevant phenotypic molecules, while Tscm and Tcm the most clinically relevant subtypes. Currently, CD27+, CD62L+ and CCR7+ are recommended in the differentiation phenotype to evaluate strategies of enhancing stemness. Future studies may discover highly clinically relevant differentiation phenotypes for specific T-cell production methods or specific subtypes of cancer patients, with the advantages of precision medicine.